Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C9H19NO2.ClH |
| Molecular Weight | 209.714 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC[C@@H](C)C[C@H](N)CC(O)=O
InChI
InChIKey=CFMZXQJDAJXNHS-WLYNEOFISA-N
InChI=1S/C9H19NO2.ClH/c1-3-4-7(2)5-8(10)6-9(11)12;/h7-8H,3-6,10H2,1-2H3,(H,11,12);1H/t7-,8+;/m1./s1
| Molecular Formula | C9H19NO2 |
| Molecular Weight | 173.2527 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Imagabalin is a ligand to the α(2)δ subunit of voltage-sensitive calcium channel and was developed to treat generalized anxiety disorder. Imagabalin was involved in phase III clinical trials when was made a decision to terminate all studies. However, this decision was not based on any safety concerns.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00738738
Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:20:17 GMT 2025
by
admin
on
Mon Mar 31 18:20:17 GMT 2025
|
| Record UNII |
MJ3F8ZA7Q1
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C28197
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
UU-112
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
610300-00-0
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
DBSALT002136
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
300000044507
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
11701275
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
MJ3F8ZA7Q1
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103836
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
DTXSID40976533
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY | |||
|
C83786
Created by
admin on Mon Mar 31 18:20:17 GMT 2025 , Edited by admin on Mon Mar 31 18:20:17 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |